Overview

A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related toxicities. Therefore, the investigators hypothesize that by transitioning patients from tacrolimus immediate release to Envarsus ®, the peak-dose effect will be eliminated or attenuated, leading to a significant decrease in neurocognitive toxicities in the older patient population.

Phase:

Phase 4

Details

Lead Sponsor:

University of California, Davis

Collaborator:

Veloxis Pharmaceuticals

Treatments:

Tacrolimus